Intellia Therapeutics, Inc. $NTLA Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 101.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 79,664 shares of the company’s stock after buying an additional 40,078 shares during the period. Profund Advisors LLC’s holdings in Intellia Therapeutics were worth $716,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of NTLA. Contrarius Group Holdings Ltd boosted its position in shares of Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after acquiring an additional 4,337,428 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after acquiring an additional 1,965,181 shares during the last quarter. Jupiter Asset Management Ltd. acquired a new stake in shares of Intellia Therapeutics in the third quarter worth approximately $23,519,000. Farallon Capital Management LLC purchased a new position in Intellia Therapeutics in the third quarter valued at approximately $10,486,000. Finally, Steadfast Capital Management LP purchased a new position in Intellia Therapeutics in the third quarter valued at approximately $6,310,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. William Blair upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, March 2nd. JonesTrading upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Wednesday, March 4th. Leerink Partners set a $35.00 price target on shares of Intellia Therapeutics in a report on Monday, April 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st. Finally, Citizens Jmp raised their price target on shares of Intellia Therapeutics from $28.00 to $30.00 and gave the company a “market outperform” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.25.

Intellia Therapeutics Stock Up 1.9%

NTLA opened at $12.60 on Friday. The firm has a market capitalization of $1.76 billion, a P/E ratio of -3.56 and a beta of 1.93. The firm’s 50 day moving average is $13.53 and its 200-day moving average is $11.96. Intellia Therapeutics, Inc. has a 52-week low of $6.83 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. The company had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter last year, the firm posted ($1.10) earnings per share. Equities analysts expect that Intellia Therapeutics, Inc. will post -3.31 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.